Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

Authors :: M. Gramatzki
J.T. Fischer
I.-M. von Broen
R. Henke
J. Oertel
E. Schäfer
J. Selbach
R. Coldewey
H. Wagner
R. Hein
H. J. Braun
Deicher H
D. Peest
M. Planker
C. Tirier
R. Leo
H. Bartels
W. Stenzinger
C.R. Meier
E. Schumacher
L. Hoffmann
M. Stennes
K. Schumacher
E. D. Kreuser
W. D. Maier
J. Wysk
R. Bartl
H. J. Weh
H.M. Reinhold
Source :: Oncology Research and Treatment. 13:458-460
Publication Year :: 1990
Publisher :: S. Karger AG, 1990.
Abstract: 277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observat

Subjects :: Oncology
Melphalan
Cancer Research
medicine.medical_specialty
Vincristine
business.industry
Induction chemotherapy
Hematology
medicine.disease
Prednisone
Interferon
Internal medicine
Multicenter trial
medicine
business
Dexamethasone
Multiple myeloma
medicine.drug

Tools